



US00552281A

United States Patent [19]

Stashenko et al.

[11] Patent Number: 5,552,281

[45] Date of Patent: Sep. 3, 1996

[54] HUMAN OSTEOCLAST-SPECIFIC AND -RELATED GENES

[75] Inventors: Philip Stashenko, Norfolk; Yi-Ping Li, Boston; Anne L. Wucherpfennig, Brookline, all of Mass.

[73] Assignee: Forsyth Dental Infirmary for Children, Boston, Mass.

[21] Appl. No.: 392,678

[22] Filed: Feb. 23, 1995

Related U.S. Application Data

[63] Continuation of Ser. No. 45,270, Apr. 6, 1993, abandoned.

[51] Int. Cl.⁶ C07H 21/04; C12N 5/10; C12N 15/70; C12Q 1/68

[52] U.S. Cl. 435/6; 435/69.1; 435/172.3; 435/252.3; 435/320.1; 536/23.1

[58] Field of Search 435/6, 320.1, 252.3, 435/69.1, 172.3; 536/23.1

[56] References Cited

PUBLICATIONS

Blair, Harry C., et al., "Extracellular-matrix degradation at acid pH. Avian osteoclast acid collagenase isolation and characterization", *Biochemical Journal* 290(3):873-884 (15 Mar. 1993).Tezuka, Ken-Ichi, et al., "Identification of osteopontin in isolated rabbit osteoclasts", *Biochemical and Biophysical Research Communications* 186(2):914-916 (31 Jul. 1992).Tezuka, Ken-Ichi, et al., "Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts", *Journal of Biological Chemistry* 269(2):1106-1108, (14 Jan. 1994).Horton, Michael A. et al., "Monoclonal Antibodies to Osteoclastomas (Giant Cell Bone Tumors): Definition of Osteoclast-specific Cellular Antigens," *Cancer Research* 45, 5663-5669 (Nov. 1985).Davies, John et al., "The Osteoclast Functional Antigen, Implicated in the Regulation of Bone Resorption, Is Biochemically Related to the Vitronectin Receptor," *The Journal of Cell Biology* 109, 1817-1826 (Oct. 1989).Hayman, Alison, R. et al., "Purification and characterization of a tartrate-resistant acid phosphatase from human osteoclastomas," *Biochem. J.* 261, 601-609 (1989).Sandberg, M. et al., "Localization of the Expression of Types I, III, and IV Collagen, TGF- β 1 and c-fos Genes in Developing Human Calvarial Bones," *Developmental Biology* 130, 324-334 (1988).Sandberg, M. et al., "Enhanced expression of TGF- β and c-fos mRNAs in the growth plates of developing human long bones," *Development* 102, 461-470 (1988).Ek-Rylander, Barbro et al., "Cloning, Sequence, and Developmental Expression of a Type 5, Tartrate-resistant, Acid Phosphatase of Rat Bone," *The Journal of Biological Chemistry* 266(36), 24684-24689 (Dec. 25, 1991).

GenBank/EMBL Sequence Search Printout, pp. 1-19 (Jun. 24, 1993).

Primary Examiner—W. Gary Jones

Assistant Examiner—Paul B. Tran

Attorney, Agent, or Firm—Hamilton, Brook, Smith & Reynolds, P.C.

[57] ABSTRACT

The present invention relates to purified DNA sequences encoding all or a portion of an osteoclast-specific or -related gene products and a method for identifying such sequences. The invention also relates to antibodies directed against an osteoclast-specific or -related gene product. Also claimed are DNA constructs capable of replicating DNA encoding all or a portion of an osteoclast-specific or -related gene product, and DNA constructs capable of directing expression in a host cell of an osteoclast-specific or -related gene product.

5 Claims, 1 Drawing Sheet

1 AGAAGCTCT GGGTGGG TGGGCTT GGGGCTT GGGGCTT GGGGCTT
2 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
3 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
4 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
5 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
6 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
7 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
8 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
9 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
10 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
11 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
12 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
13 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
14 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
15 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
16 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
17 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
18 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
19 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
20 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
21 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
22 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
23 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
24 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
25 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
26 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
27 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
28 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
29 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
30 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
31 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
32 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
33 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
34 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
35 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
36 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
37 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
38 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
39 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
40 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
41 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
42 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
43 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
44 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
45 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
46 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
47 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
48 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
49 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
50 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
51 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
52 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
53 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
54 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
55 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
56 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
57 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
58 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
59 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
60 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
61 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
62 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
63 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
64 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
65 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
66 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
67 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
68 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
69 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
70 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
71 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
72 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
73 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
74 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
75 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
76 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
77 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
78 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
79 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
80 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
81 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
82 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
83 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
84 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
85 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
86 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
87 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
88 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
89 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
90 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
91 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
92 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
93 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
94 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
95 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
96 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
97 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
98 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
99 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT
100 GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT GGGGCTT

1 AGACACCTCT GCCCTCACCA TGAGCCTCTG GCAGCCCCTG GTCCTGGTGC TCCTGGTGCT
61 GGGCTGCTGC TTTGCTGCCC CCAGACAGCG CCAGTCCACC CTTGTGCTCT TCCCTGGAGA
121 CCTGAGAACC AATCTCACCG ACAGGCAGCT GGCAGAGGAA TACCTGTACC GCTATGGTTA
181 CACTCGGGTG GCAGAGATGC GTGGAGAGTC GAAATCTCTG GGGCCTGCGC TGCTGCTTCT
241 CCAGAAGCAA CTGTCCCTGC CCAGACCGG TGAGCTGGAT AGCGCCACGC TGAAGGCCAT
301 GCGAACCCCA CGGTGCGGGG TCCCAGACCT GGGCAGATTG CAAACCTTTG AGGGCGACCT
361 CAAGTGGCAC CACCACAACA TCACCTATTG GATCCAAAAC TACTCGGAAG ACTTGCCGCG
421 GGCGGTGATT GACGACGCCT TTGCCGCGC CTTGCACTG TGGAGCGCGG TGACGCCGCT
481 CACCTTCACT CGCGTGTA CA GCGGGACGC AGACATCGTC ATCCAGTTTG GTGTCGCGGA
541 GCACGGAGAC GGGTATCCCT TCGACGGGAA GGACGGGCTC CTGGCACACG CCTTTCCTCC
601 TGGCCCCGCG ATTCAAGGAG ACGCCCATTT CGACGATGAC GAGTTGTGGT CCCTGGGCAA
661 GGGCGTCGTG GTTCCAATC GGTTTGGAAA CGCAGATGGC GCGGCCTGCC ACTTCCCTT
721 CATCTTCGAG GGCCGCTCCT ACTCTGCCTG CACCACCGAC GGTGCTCCG ACGGGTTGCC
781 CTGGTGCAGT ACCACGGCCA ACTACGACAC CGACGACCGG TTGGGCTTCT GCGCCAGCGA
841 GAGACTCTAC ACCCGGGACG GCAATGCTGA TGGGAAACCC TGCCAGTTTC CATTATCTT
901 CCAAGGCCAA TCCTACTCCG CCTGCACCAC GGACGGTCGC TCCGACGGCT ACCGCTGTG
961 CGCCACCACC GCCAACTACG ACGGGACAA GCTCTTCGGC TTCTGCCCCG CCCGAGCTGA
1021 CTCGACGGTG ATGGGGGGCA ACTCGGCGGG GGAGCTGTGC GTCTTCCCT TCACTTTCCT
1081 GGGTAAGGAG TACTCGACCT GTACCAGCGA GGGCCGCGGA GATGGGCGCC TCTGGTGC
1141 TACCACCTCG AACTTTGACA GCGACAAGAA GTGGGGCTTC TGCCCGGACC AAGGATACAG
1201 TTGTTCCTC GTGGCGCGC ATGAGTTCGG CCACGCGCTG GGCTTAGATC ATTCCTCAGT
1261 GCCGGAGGCG CTCATGTACC CTATGTACCG CTTCACTGAG GGGCCCCCT TGCATAAGGA
1321 CGACGTGAAT GGCATCCGGC ACCTCTATGG TCCTCGCCCT GAACCTGAGC CACGGCCTCC
1381 AACCACCACC ACACCGCAGC CCACGGCTCC CCCGACGGTC TGCCCCACCG GACCCCCAC
1441 TGTCCACCCC TCAGAGCGCC CCACAGCTGG CCCCACAGGT CCCCCCTCAG CTGGCCCCAC
1501 AGGTCCCCC ACTGCTGGCC CTTCTACGGC CACTACTGTG CTTTGAGTC CGGTGGACGA
1561 TGCCTGCAAC GTGAACATCT TCGACGCCAT CGCGGAGATT GGGAACCAGC TGTATTTGTT
1621 CAAGGATGGG AAGTACTGGC GATTCTCTGA GGGCAGGGG AGCCGGCCGC AGGGCCCCCT
1681 CCTTATCGCC GACAAGTGGC CCGCGCTGCC CCGCAAGCTG GACTCGGTCT TTGAGGAGCC
1741 GCTCTCCAAG AAGCTTTTCT TCTTCTCTGG GCGCCAGGTG TGGGTGTACA CAGGCGCGTC
1801 GGTGCTGGGC CCGAGGCGTC TGGACAAGCT GGGCCTGGGA GCGACGTGG CCCAGGTGAC
1861 CGGGGCCCTC CGGAGTGGCA GGGGAAGAT GCTGCTGTTC AGCGGGCGGC GCCTCTGGAG
1921 GTTCGACGTG AAGGCGCAGA TGGTGGATCC CCGGAGCGCC AGCGAGGTGG ACCGGATGTT
1981 CCCCGGGGTG CCTTTGGACA CGCACGACGT CTTCCAGTAC CGAGAGAAAG CCTATTTCTG
2041 CCAGGACCGC TTCTACTGGC GCGTGAGTTC CCGGAGTGAG TTGAACCAGG TGGACCAAGT
2101 GGGCTACGTG ACCTATGACA TCCTGCAGTG CCCTGAGGAC TAGGGCTCCC GTCCTGCTT
2161 GCAGTGCCAT GTAAATCCCC ACTGGGACCA ACCCTGGGGA AGGAGCCAGT TTGCCGATA
2221 CAAACCTGGTA TTCTGTTCTG GAGGAAAGGG AGGAGTGGAG GTGGGCTGGG CCCTCTCTC
2281 TCACCTTTGT TTTTGTGG AGTGTCTTA ATAACTGG ATTCTTAAC CTTT

Figure 1

HUMAN OSTEOCLAST-SPECIFIC AND -RELATED GENES

RELATED APPLICATION

This application is a continuation of application Ser. No. 08/045,270 filed on Apr. 6, 1993 now abandoned.

BACKGROUND OF THE INVENTION

Excessive bone resorption by osteoclasts contributes to the pathology of many human diseases including arthritis, osteoporosis, periodontitis, and hypercalcemia of malignancy. During resorption, osteoclasts remove both the mineral and organic components of bone (Blair, H. C., et al., *J. Cell Biol.* 102:1164 (1986)). The mineral phase is solubilized by acidification of the sub-osteoclastic lacuna, thus allowing dissolution of hydroxyapatite (Vaes, G., *Clin. Orthop. Relat.* 231:239 (1988)). However, the mechanism(s) by which type I collagen, the major structural protein of bone, is degraded remains controversial. In addition, the regulation of osteoclastic activity is only partly understood. The lack of information concerning osteoclast function is due in part to the fact that these cells are extremely difficult to isolate as pure populations in large numbers. Furthermore, there are no osteoclastic cell lines available. An approach to studying osteoclast function that permits the identification of heretofore unknown osteoclast-specific or -related genes and gene products would allow identification of genes and gene products that are involved in the resorption of bone and in the regulation of osteoclastic activity. Therefore, identification of osteoclast-specific or -related genes or gene products would prove useful in developing therapeutic strategies for the treatment of disorders involving aberrant bone resorption.

SUMMARY OF THE INVENTION

The present invention relates to isolated DNA sequences encoding all or a portion of osteoclast-specific or -related gene products. The present invention further relates to DNA constructs capable of replicating DNA encoding osteoclast-specific or -related gene products. In another embodiment, the invention relates to a DNA construct capable of directing expression of all or a portion of the osteoclast-specific or -related gene product in a host cell.

Also encompassed by the present invention are prokaryotic or eukaryotic cells transformed or transfected with a DNA construct encoding all or a portion of an osteoclast-specific or -related gene product. According to a particular embodiment, these cells are capable of replicating the DNA construct comprising the DNA encoding the osteoclast-specific or -related gene product, and, optionally, are capable of expressing the osteoclast-specific or -related gene product. Also claimed are antibodies raised against osteoclast-specific or -related gene products, or portions of these gene products.

The present invention further embraces a method of identifying osteoclast-specific or -related DNA sequences and DNA sequences identified in this manner. In one embodiment, cDNA encoding osteoclast is identified as follows: First, human giant cell tumor of the bone was used to 1) construct a cDNA library; 2) produce ³²P-labelled cDNA to use as a stromal cell⁺; osteoclast⁺ probe, and 3) produce (by culturing) a stromal cell population lacking osteoclasts. The presence of osteoclasts in the giant cell tumor was confirmed by histological staining for the osteo-

clast marker, type 5 tartrate-resistant acid phosphatase (TRAP) and with the use of monoclonal antibody reagents.

The stromal cell population lacking osteoclasts was produced by dissociating cells of a giant cell tumor, then growing and passaging the cells in tissue culture until the cell population was homogeneous and appeared fibroblastic. The cultured stromal cell population did not contain osteoclasts. The cultured stromal cells were then used to produce a stromal cell⁺, osteoclast⁻ ³²P-labelled cDNA probe.

The cDNA library produced from the giant cell tumor of the bone was then screened in duplicate for hybridization to the cDNA probes: one screen was performed with the giant cell tumor cDNA probe (stromal cell⁺, osteoclast⁺), while a duplicate screen was performed using the cultured stromal cell cDNA probe (stromal cell⁺, osteoclast⁻). Hybridization to a stromal⁺, osteoclast⁺ probe, accompanied by failure to hybridize to a stromal⁺, osteoclast⁻ probe indicated that a clone contained nucleic acid sequences specifically expressed by osteoclasts.

In another embodiment, genomic DNA encoding osteoclast-specific or -related gene products is identified through known hybridization techniques or amplification techniques. In one embodiment, the present invention relates to a method of identifying DNA encoding an osteoclast-specific or -related protein, or gene product, by screening a cDNA library or a genomic DNA library with a DNA probe comprising one or more sequences selected from the group consisting of the DNA sequences set out in Table I (SEQ ID NOs: 1-32). Finally, the present invention relates to an osteoclast-specific or related protein encoded by a nucleotide sequence comprising a DNA sequence selected from the group consisting of the sequences set out in Table I, or their complementary strands.

BRIEF DESCRIPTION OF FIG. 1

The FIG. 1 shows cDNA sequence (SEQ ID NO: 33) of human gelatinase B, and highlights those portions of the sequence represented by the osteoclast-specific or -related cDNA clones of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

As described herein, Applicant has identified osteoclast-specific or osteoclast-related nucleic acid sequences. These sequences were identified as follows: Human giant cell tumor of the bone was used to 1) construct a cDNA library; 2) produce ³²P-labelled cDNA to use as a stromal cell⁺, osteoclast⁺ probe, and 3) produce (by culturing) a stromal cell population lacking osteoclasts. The presence of osteoclasts in the giant cell tumor was confirmed by histological staining for the osteoclast marker, type 5 acid phosphatase (TRAP). In addition, monoclonal antibody reagents were used to characterize the multinucleated cells in the giant cell tumor, which cells were found to have a phenotype distinct from macrophages and consistent with osteoclasts.

The stromal cell population lacking osteoclasts was produced by dissociating cells of a giant cell tumor, then growing the cells in tissue culture for at least five passages. After five passages the cultured cell population was homogeneous and appeared fibroblastic. The cultured population contained no multinucleated cells at this point, tested negative for type 5 acid phosphatase, and tested variably alkaline phosphatase positive. That is, the cultured stromal cell population did not contain osteoclasts. The cultured stromal

3

cells were then used to produce a stromal cell⁺, osteoclast⁻ ³²P-labelled cDNA probe.

The cDNA library produced from the giant cell tumor of the bone was then screened in duplicate for hybridization to the cDNA probes: one screen was performed with the giant cell tumor cDNA probe (stromal cell⁺, osteoclast⁻), while a duplicate screen was performed using the cultured stromal cell cDNA probe (stromal cell⁺ osteoclast⁻). Clones that hybridized to the giant cell tumor cDNA probe (stromal⁺, osteoclast⁻), but not to the stromal cell cDNA probe (stromal⁺, osteoclast⁻), were assumed to contain nucleic acid sequences specifically expressed by osteoclasts.

As a result of the differential screen described herein, DNA specifically expressed in osteoclast cells characterized as described herein was identified. This DNA, and equivalent DNA sequences, is referred to herein as osteoclast-specific or osteoclast-related DNA. Osteoclast-specific or -related DNA of the present invention can be obtained from sources in which it occurs in nature, can be produced recombinantly or synthesized chemically; it can be cDNA, genomic DNA, recombinantly-produced DNA or chemically-produced DNA. An equivalent DNA sequence is one which hybridizes, under standard hybridization conditions, to an osteoclast-specific or -related DNA identified as described herein or to a complement thereof.

Differential screening of a human osteoclastoma cDNA library was performed to identify genes specifically expressed in osteoclasts. Of 12,000 clones screened, 195 clones were identified which are either uniquely expressed in osteoclasts, or are osteoclast-related. These clones were further identified as osteoclast-specific, as evidenced by failure to hybridize to mRNA derived from a variety of unrelated human cell types, including epithelium, fibroblasts, lymphocytes, myelomonocytic cells, osteoblasts, and neuroblastoma cells. Of these, 32 clones contain novel cDNA sequences which were not found in the GenBank database.

A large number of cDNA clones obtained by this procedure were found to represent 92 kDa type IV collagenase (gelatinase B; E.C. 3.4.24.35) as well as tartrate resistant acid phosphatase. In situ hybridization localized mRNA for gelatinase B to multinucleated giant cells in human osteoclastomas. Gelatinase B immunoreactivity was demonstrated in giant cells from 8/8 osteoclastomas, osteoclasts in normal bone, and in osteoclasts of Paget's disease by use of a polyclonal antiserum raised against a synthetic gelatinase B peptide. In contrast, no immunoreactivity for 72 kDa type IV collagenase (gelatinase A; E.C. 3.4.24.24), which is the product of a separate gene, was detected in osteoclastomas or normal osteoclasts.

The present invention has utility for the production and identification of nucleic acid probes useful for identifying osteoclast-specific or -related DNA. Osteoclast-specific or -related DNA of the present invention can be used to produce osteoclast-specific or -related gene products useful in the therapeutic treatment of disorders involving aberrant bone resorption. The osteoclast-specific or -related sequences are also useful for generating peptides which can then be used to produce antibodies useful for identifying osteoclast-specific or -related gene products, or for altering the activity of osteoclast-specific or -related gene products. Such antibodies are referred to as osteoclast-specific antibodies. Osteoclast-specific antibodies are also useful for identifying osteoclasts. Finally, osteoclast-specific or -related DNA sequences of the present invention are useful in gene therapy. For example, they can be used to alter the

4

expression in osteoclasts of an aberrant osteoclast-specific or -related gene product or to correct aberrant expression of an osteoclast-specific or -related gene product. The sequences described herein can further be used to cause osteoclast-specific or related gene expression in cells in which such expression does not ordinarily occur, i.e., in cells which are not osteoclasts.

Example 1—Osteoclast cDNA Library Construction

Messenger RNA (mRNA) obtained from a human osteoclastoma ("giant cell tumor of bone"), was used to construct an osteoclastoma cDNA library. Osteoclastomas are actively bone resorptive tumors, but are usually non-metastatic. In cryostat sections, osteoclastomas consist of ~30% multinucleated cells positive for tartrate resistant acid phosphatase (TRAP), a widely utilized phenotypic marker specific in vivo for osteoclasts (Minkin, *Calcif. Tissue Int.* 34:285-290 (1982)). The remaining cells are uncharacterized 'stromal' cells, a mixture of cell types with fibroblastic/mesenchymal morphology. Although it has not yet been definitively shown, it is generally held that the osteoclasts in these tumors are non-transformed, and are activated to resorb bone in vivo by substance(s) produced by the stromal cell element.

Monoclonal antibody reagents were used to partially characterize the surface phenotype of the multinucleated cells in the giant cell tumors of long bone. In frozen sections, all multinucleated cells expressed CD68, which has previously been reported to define an antigen specific for both osteoclasts and macrophages (Horton, M. A. and M. H. Helfrich, In *Biology and Physiology of the Osteoclast*, B. R. Rifkin and C. V. Gay, editors, CRC Press, Inc. Boca Raton, Fla., 33-54 (1992)). In contrast, no staining of giant cells was observed for CD11b or CD14 surface antigens, which are present on monocyte/macrophages and granulocytes (Arnaout, M. A. et al. *J. Cell. Physiol.* 137:305 (1988); Haziot, A. et al. *J. Immunol.* 141:547 (1988)). Cytocentrifuge preparations of human peripheral blood monocytes were positive for CD68, CD11b, and CD14. These results demonstrate that the multinucleated giant cells of osteoclastomas have a phenotype which is distinct from that of macrophages, and which is consistent with that of osteoclasts.

Osteoclastoma tissue was snap frozen in liquid nitrogen and used to prepare poly A⁺ mRNA according to standard methods. cDNA cloning into a pcDNAII vector was carried out using a commercially-available kit (Librarian, InVitrogen). Approximately 2.6×10⁶ clones were obtained, >95% of which contained inserts of an average length 0.6 kb.

Example 2—Stromal Cell mRNA Preparation

A portion of each osteoclastoma was snap frozen in liquid nitrogen for mRNA preparation. The remainder of the tumor was dissociated using brief trypsinization and mechanical disaggregation, and placed into tissue culture. These cells were expanded in Dulbecco's MEM (high glucose, Sigma) supplemented with 10% newborn calf serum (MA Bioproducts), gentamycin (0.5 mg/ml), l-glutamine (2 mM) and non-essential amino acids (0.1 mM) (Gibco). The stromal cell population was passaged at least five times, after which it showed a homogenous, fibroblastic looking cell population that contained no multinucleated cells. The stromal cells were mononuclear, tested negative acid phosphatase, and tested variably alkaline phosphatase positive. These findings indicate that propagated stromal cells (i.e., stromal cells that

are passaged in culture) are non-osteoclastic and non-activated.

Example 3—Identification of DNA Encoding Osteoclastoma-Specific or -Related Gene Products by Differential Screening of an Osteoclastoma cDNA Library

A total of 12,000 clones drawn from the osteoclastoma cDNA library were screened by differential hybridization, using mixed ^{32}P labelled cDNA probes derived from (1) giant cell tumor mRNA (stromal cell⁺, OC⁺), and (2) mRNA from stromal cells (stromal cell⁺, OC⁺) cultivated from the same tumor. The probes were labelled with ^{32}P dCTP by random priming to an activity of $\sim 10^6\text{CPM}/\mu\text{g}$. Of these 12,000 clones, 195 gave a positive hybridization signal with giant cell (i.e., osteoclast and stromal cell) mRNA, but not with stromal cell mRNA. Additionally, these clones failed to hybridize to cDNA produced from mRNA derived from a variety of unrelated human cell types including epithelial cells, fibroblasts, lymphocytes, myelomonocytic cells, osteoblasts, and neuroblastoma cells. The failure of these clones to hybridize to cDNA produced from mRNA derived from other cell types supports the conclusion that these clones are either uniquely expressed in osteoclasts, or are osteoclast-related.

The osteoclast (OC) cDNA library was screened for differential hybridization to OC cDNA (stromal cell⁺, OC⁺) and stromal cell cDNA (stromal cell⁺, OC⁻) as follows:

NYTRAN filters (Schleicher & Schuell) were placed on agar plates containing growth medium and ampicillin. Individual bacterial colonies from the OC library were randomly picked and transferred, in triplicate, onto filters with pre-ruled grids and then onto a master agar plate. Up to 200 colonies were inoculated onto a single 90-mm filter/plate using these techniques. The plates were inverted and incubated at 37° C. until the bacterial inoculates had grown (on the filter) to a diameter of 0.5–1.0 mm.

The colonies were then lysed, and the DNA bound to the filters by first placing the filters on top of two pieces of Whatman 3 MM paper saturated with 0.5N NaOH for 5 minutes. The filters were neutralized by placing on two pieces of Whatman 3 MM paper saturated with 1M Tris-HCl, pH 8.0 for 3–5 minutes. Neutralization was followed by incubation on another set of Whatman 3 MM papers saturated with 1M Tris-HCl, pH 8.0/1.5M NaCl for 3–5 minutes. The filters were then washed briefly in 2xSSC.

DNA was immobilized on the filters by baking the filters at 80° C. for 30 minutes. Filters were best used immediately, but they could be stored for up to one week in a vacuum jar at room temperature.

Filters were prehybridized in 5–8 ml of hybridization solution per filter, for 2–4 hours in a heat sealable bag. An additional 2 ml of solution was added for each additional filter added to the hybridization bag. The hybridization

buffer consisted of 5xSSC, 5xDenhardt's solution, 1% SDS and 100 $\mu\text{g}/\text{ml}$ denatured heterologous DNA.

Prior to hybridization, labeled probe was denatured by heating in 1xSSC for 5 minutes at 100° C., then immediately chilled on ice. Denatured probe was added to the filters in hybridization solution, and the filters hybridized with continuous agitation for 12–20 hours at 65° C.

After hybridization, the filters were washed in 2xSSC/0.2% SDS at 50°–60° C. for 30 minutes, followed by washing in 0.2xSSC/0.2% SDS at 60° C. for 60 minutes.

The filters were then air dried and autoradiographed using an intensifying screen at -70° C. overnight.

Example 4—DNA Sequencing of Selected Clones

Clones reactive with the mixed tumor probe, but unreactive with the stromal cell probe, are expected to contain either osteoclast-related, or in vivo 'activated' stromal-cell-related gene products. One hundred and forty-four cDNA clones that hybridized to tumor cell cDNA, but not to stromal cell cDNA, were sequenced by the dideoxy chain termination method of Sanger et al. (Sanger F., et al. *Proc. Natl. Acad. Sci. USA* 74:5463 (1977)) using sequenase (US Biochemical). The DNASIS (Hitachi) program was used to carry out sequence analysis and a homology search in the GenBank/EMBL database.

Fourteen of the 195 tumor⁺ stromal⁻ clones were identified as containing inserts with a sequence identical to the osteoclast marker, type 5 tartrate-resistant acid phosphatase (TRAP) (GenBank accession number J04430 M19534). The high representation of TRAP positive clones also indicates the effectiveness of the screening procedure in enriching for clones which contain osteoclast-specific or related cDNA sequences.

Interestingly, an even larger proportion of the tumor⁺ stromal⁻ clones (77/195; 39.5%) were identified as human gelatinase B (macrophage-derived gelatinase) (Wilhelm, S. M. *J. Biol. Chem.* 264:17213 (1989)), again indicating high expression of this enzyme by osteoclasts. Twenty-five of the gelatinase B clones were identified by dideoxy sequence analysis; all 25 showed 100% sequence homology to the published gelatinase B sequence (Genbank accession number J05070). The portions of the gelatinase B cDNA sequence covered by these clones is shown in the FIGURE (SEQ ID NO: 33). An additional 52 gelatinase B clones were identified by reactivity with a ^{32}P -labelled probe for gelatinase B.

Thirteen of the sequenced clones yielded no readable sequence. A DNASIS search of GenBank/EMBL databases revealed that, of the remaining 91 clones, 32 clones contain novel sequences which have not yet been reported in the databases or in the literature. These partial sequences were presented in Table I. Note that three of these sequences were repeats, indicating fairly frequent representation of mRNA related to this sequence. The repeat sequences are indicated by ^{a, b} superscripts (Clones 198B, 223B and 32C of Table I).

TABLE I

PARTIAL SEQUENCES OF 32 NOVEL OC-SPECIFIC OR -RELATED EXPRESSED GENES (cDNA CLONES)

| | | | | | |
|--------------------|------------|------------|------------|------------|------------|
| 34A (SEQ ID NO: 1) | | | | | |
| 1 GCAAATATCT | AAGTTTATTG | CITGGATTTC | TAGTGAGAGC | TGTTGAATT | GGTGATGTCA |
| 61 AATGTTTCTA | GGGTTTITTT | AGTTTGTTT | TATTGAAAAA | TTTAATTAT | TATGCTATAG |
| 121 GTGATATCT | CTTTGAATAA | ACCTATAATA | GAAATAGCA | GCAGACAACA | |
| 4B (SEQ ID NO: 2) | | | | | |
| 1 GTGTCAACCT | GCATATCCTA | AAAATGTCAA | AATGCTGCAT | CTGTTAATG | TCGGGGTAGG |

TABLE I-continued

| PARTIAL SEQUENCES OF 32 NOVEL OC-SPECIFIC OR -RELATED EXPRESSED GENES (cDNA CLONES) | | | | | | |
|--|-------------|-------------|------------|------------|------------|--|
| 61 GGG | | | | | | |
| 12B (SEQ ID NO: 3) | | | | | | |
| 1 CTTCCTCTC | TTGCTTCCT | TTCCCAAGCA | GAGGTGCTCA | CTCCATGGCC | ACCGCCACCA | |
| 61 CAGGCCACA | GGGAGTACTG | CCAGACTACT | GCTGATGTC | TCTTAAGGCC | CAGGGAGTCT | |
| 121 CAACCAGCTG | GTGGTGAATG | CTGCCGGCA | CGGGACCC | CCC | | |
| 28B (SEQ ID NO: 4) | | | | | | |
| 1 TTTTATTGT | AAATATATGT | ATTACATCCC | TAGAAAAAGA | ATCCCAGGAT | TTCCCTCTC | |
| 61 GTGTGTTTC | GTCTTGCTTC | TTCATGCTCC | ATGATGCCAG | CTGAGGTTGT | CAGTACAATG | |
| 121 AAACCAAACT | GCGGGATGG | AAGCAGATTA | TTCTGCCATT | TTCCAGGTC | TTT | |
| 37B (SEQ ID NO: 5) | | | | | | |
| 1 GGCTGGACAT | GGGTGCCCTC | CACGTCCCTC | ATATCCCCAG | GCACACTCTG | GCCTCAGGTT | |
| 61 TTGCCCTGGC | CATGTCATCT | ACCTGGAAGT | GGCCCTCCCC | TTCTTCAGCC | TTGAATCAAA | |
| 121 AGCCACTTTG | TTAGGGGAGG | ATTGCCAGA | CCACTCATCA | CATTAAAAAA | TATTTTGA | |
| 181 ACAAAAAAAA | AAAAAA | | | | | |
| 55B (SEQ ID NO: 6) | | | | | | |
| 1 TTGACAAAGC | TGTTTATTTT | CACCAATAAA | TAGTATATGG | TGATTGGGGT | TTCTATTTAT | |
| 61 AAGAGTAGTG | GCTATTATAT | GGGTATCAT | GTTGATGCTC | ATAAATAGTT | CATATCTACT | |
| 121 TAATTTGCCT | TC | | | | | |
| 60B (SEQ ID NO: 7) | | | | | | |
| 1 GAAGAGAGTT | GTATGTACAA | CCCAACAGG | CAAGGCAGCT | AAATGCAGAG | GGTACAGAGA | |
| 61 GATCCCGAGG | GAATT | | | | | |
| 86B (SEQ ID NO: 8) | | | | | | |
| 1 GGATGGAAAC | ATGTAGAAGT | CCAGAGAAAA | ACAATTTTAA | AAAAAGGTGG | AAAAGTTACG | |
| 61 GCAAACTGA | GATTTTCAGCA | TAAAACTTTT | AGTTAGAAGT | GAAGAGAAAG | AGAGGGAGGC | |
| 121 TGGTTGCTGT | TGCACGTATC | AATAGGTTAT | C | | | |
| 87B (SEQ ID NO: 9) | | | | | | |
| 1 TTCTTGATCT | TTAGAACACT | ATGAATAGGG | AAAAAGAAAA | AAACTGTTCA | AAATAAAATG | |
| 61 TAGGAGCCGT | GCTTTTGGAA | TGCTTGAGTG | AGGAGCTCAA | CAAGTCCTCT | CCCAAGAAAG | |
| 181 CAATGATAAA | ACTTGACAAA | A | | | | |
| 98B (SEQ ID NO: 10) | | | | | | |
| 1 ACCCATTTCT | AACAATTTTT | ACTGTAAAAAT | TTTTGGTCAA | AGTTCTAAGC | TTAATCACAT | |
| 61 CTCAAAAGAT | AGAGGCAATA | TATAGCCCAT | CTTACTAGAC | ATACAGTATT | AAACTGGACT | |
| 121 GAATATGAGG | ACAAGCTCTA | GTGGTCATTA | AACCCCTCAG | AA | | |
| 110B (SEQ ID NO: 11) | | | | | | |
| 1 ACATATATTA | ACAGCATTC | TTTGGCCAAA | ATCTACACGT | TTGTAGAATC | CTACTGTATA | |
| 61 TAAAGTGGGA | ATGTATCAAG | TATAGACTAT | GAAAGTGCAA | ATAACAAGTC | AAGGTTAGAT | |
| 121 TAACTTTTTT | TTTTTACATT | ATAAAAATTA | CTTGTITT | | | |
| 118B (SEQ ID NO: 12) | | | | | | |
| 1 CCAAATTTCT | CTGGAATOCA | TCCTCCCTCC | CATCACCATA | GCCTCGAGAC | GTCAATTCTG | |
| 61 TTTGACTACT | CCAGC | | | | | |
| 133B (SEQ ID NO: 13) | | | | | | |
| 1 AACTAACCTC | CTCGGACCCC | TGCTCACTC | ATTTACACCA | ACCAOCCAAC | TATCTATAAA | |
| 61 CCTGAGCCAT | GGCCATCCCT | TATGAGCGGC | QCAGTGATTA | TAGGCTTTCG | CTCTAAGATA | |
| 121 AAAT | | | | | | |
| 140B (SEQ ID NO: 14) | | | | | | |
| 1 AITATTATTC | TTTTTTTATG | TTAGCTTAGC | CATGCAAAAT | TTACTGGTGA | AGCAGTTAAT | |
| 61 AAAACACACA | TCCCATTGAA | GGGTTTGTGA | CAATTCAGTC | CTTACAAATA | ACAAGCAAT | |
| 121 GATAAACCCG | GCACGTCCTG | ATAGGAAATT | C | | | |
| 144B (SEQ ID NO: 15) | | | | | | |
| 1 CGTGACACAA | ACATGCATTC | GTTTTATTCA | TAAACAGCC | TGGTTTCTTA | AAACAATACA | |
| 61 AACAGCATGT | TCATCAGCAG | GAAGCTGGCC | GTGGGCAGGG | GGGCC | | |
| 198B* (SEQ ID NO: 16) | | | | | | |
| 1 ATAGGTTAGA | TTCTCATTC | CGGGACTAGT | TAGCTTTAAG | CACCCTAGAG | GACTAGGGTA | |
| 61 ATCTGACTTC | TCACCTCCCTA | AGTTCCCTCT | TATATCCTCA | AGGTAGAAAT | GTCTATGTTT | |
| 121 TCTACTCCAA | TTCTATAAATC | TATTCATAAG | TCTTTGGTAC | AAGTTACATG | ATAAAAGAA | |
| 181 ATGTGATTTG | TCTTCCCTTC | TTTGCACTTT | TRAAATAAAG | TATTTATCTC | CTGTCTACAG | |
| 241 TTTAAT | | | | | | |
| 212B (SEQ ID NO: 17) | | | | | | |
| 1 GTCCAGTATA | AAGGAAAGCG | TTAAGTCGGT | AAGCTAGAGG | ATTGTAAATA | TCTTTTATGT | |
| 61 CCTCTAGATA | AAACACCCGA | TTAACAGATG | TTAACCTTTT | ATGTTTGTAT | TTGCTTTAAA | |
| 121 AATGGCCTTC | TACACATTAG | CTCCAGCTAA | AAAGACACAT | TGAGAGCTTA | GAGGATAGTC | |
| 181 TCTGGAGC | | | | | | |
| 223B* (SEQ ID NO: 18) | | | | | | |
| 1 GCACTTGGAA | GGGAGTTGGT | GTGCTATTTT | TGAAGCAGAT | GTGGTGATAC | TGAAGTTGTC | |
| 61 TGTTCAGTTT | CCCCATTTGT | TTGTGCTTCA | AATGATCCTT | CCTACTTTGC | TTCTCTCCAC | |
| 121 CCATGACCTT | TTTCACTGTG | GCCATCAAGG | ACTTTCCTGA | CAGCTTGTGT | ACTCTTAGGC | |
| 181 TAAGAGATGT | GACTACAGCC | TGCCCCGAC | TG | | | |
| 241B (SEQ ID NO: 19) | | | | | | |
| 1 TGTAGTTT | TAGGAAGGCC | TGTCTTCTGG | GAGTGAGGTT | TATTAGTCCA | CTTCTTGGAG | |
| 61 CTAGAGTCC | TATAGTTAGT | CAGTGGGGAT | GGTGAAAGAG | AGGAGAAAGG | AAGGCCGAGG | |
| 121 GGAAGGGCTC | TTTGCTAGTA | TCTCCATTTC | TAGAAGATGG | TTTAGATGAT | AACCAAGGT | |
| 181 CTATATGAGC | ATAGTAAGGC | TGT | | | | |
| 32C* (SEQ ID NO: 20) | | | | | | |
| 1 CCTATTCTCTG | ATCCTGACTT | TGGACAAGGC | CCTTCAGCCA | GAAGACTGAC | AAAGTCATCC | |
| 121 TCCGTCTACC | AGAGCGTGCA | CTTGTGATCC | TAAAATAAGC | TTCTCTCCG | GCTGTGCCCT | |
| 161 GGGTGGAAGG | GGCAGGATTC | TGCAGTGCT | TTTGCAATTC | TCTTCTAAA | TTTCATT | |

TABLE I-continued

| PARTIAL SEQUENCES OF 32 NOVEL OC-SPECIFIC OR -RELATED EXPRESSED GENES (cDNA CLONES) | | | | | |
|--|------------|------------|------------|------------|------------|
| 34C (SEQ ID NO: 21) | GTGTGTTTAT | TCCTGTACAA | ATCATTACAA | AACCAAGTCT | GGGGCAGTCA |
| 1 | CGGAGCCTAG | AGTGCAATGG | CTAGCTGCTG | GCCTTT | |
| 61 | CCGCCCCAC | | | | |
| 47C (SEQ ID NO: 22) | CAAAGCAGGC | AACCCCTTT | GGCACTGCTG | CCACTGGGGT | CATGGCGTT |
| 1 | TTAGTTCAGT | CCCAACACCC | TCCTCTGCTT | CCCTGTGTGT | CGGGGTCTCA |
| 61 | GTGGCAGCTG | | | | |
| 121 | GGAGCTGACC | | | | |
| 65C (SEQ ID NO: 23) | TAAGAGAGAT | TTTGGTCTTA | AAGGCTTCAT | CATGAAAGTG | TACATGCATA |
| 1 | GCTGAATGTT | TATGGATGGT | TGCTTGTTTA | TTAACTAAAG | ATGTACAGCA |
| 61 | TGCAAGTGTG | CTTAATATTG | ATGTCTAAC | ACTGGGTCTG | CTTATGC |
| 121 | AACTGCCCCG | | | | |
| 79C (SEQ ID NO: 24) | TATGGAATCC | AGAAGGGAAA | CAAGCACTGG | ATAATTAATA | ACAGCTGGGG |
| 1 | GGCACTGGGA | GATATATCT | CATGGCTCGA | AATAAGAAC | ACGCTGTGG |
| 61 | AGAAAACCTG | TCCCAAGAT | GTGACTCCAG | CCAGAAA | |
| 121 | CATTGCCAAC | | | | |
| 84C (SEQ ID NO: 25) | ACCGTCTTTA | TTCTCTCTCT | GCCTCAGAGG | TCAGGAAGGA | GGTCTGGCAG |
| 1 | GCCAGGGCGG | CATCTGTGGC | AGCGAAGGTG | AAGGGACTCA | CCTTGTGCGC |
| 61 | GACCTGCAGT | TCTGGAATTC | C | | |
| 121 | CGTGCTGAG | | | | |
| 86C (SEQ ID NO: 26) | CACTCTGGTA | TTTTTAGTTT | AACAATATAT | GTGTTGTGTC | TTGGAAATTA |
| 1 | AACTCTTTCA | AGCTGTCTCA | TTCTTTTTTT | AATGGTCATA | TACAGTAGTA |
| 61 | GTTCATATCA | CTAATACCTT | TTAAAA | | |
| 121 | TTCAATTATA | | | | |
| 87C (SEQ ID NO: 27) | GAAGGCCTGA | GGCCTAGGGG | CCGRGGCTGG | CCTGCGTCTC | AGTCTGGGA |
| 1 | GGATAAGAAA | GAGAGGGGCA | CTTCTCTTG | CTTAGGTG | TGAGGATCTG |
| 61 | CGCAGCAGCC | AGCCACAAAA | | | |
| 121 | GTCTGTGTTG | | | | |
| 88C (SEQ ID NO: 28) | AGAGTTTGAC | CTGGAGCCGG | ATACCTACTG | CCGCTATGAC | TCGGTCAGCG |
| 1 | CTGACCTTCG | GACGACTCCG | GTGGGGAAGT | TCTGCGGCGA | T |
| 61 | TGTTCAACGG | | | | |
| 89C (SEQ ID NO: 29) | GTGGATAGTG | CTTTGTGTGA | GCAATGCTC | CCTCCTTAAG | GTATAGGGC |
| 1 | ATCCCTGGCT | TGGAGTGTG | TTAAGTGTCT | GTCTGCTTG | GCTGTGTTA |
| 61 | TCCTGTGAGT | GCTAACATA | AGAATAC | | |
| 121 | TCGTTTTCTG | | | | |
| 101C (SEQ ID NO: 30) | CCCTCTCTC | CTCCATCCCC | ATACATCACC | AGGTCTAATG | TTTACAAACG |
| 1 | GGCTGGGCAT | CCAAGGGCCG | TCCGTGCCAC | GGTGGCTGTG | AGTATCTCTC |
| 61 | GTGCCAGCCC | TGGAGTATCT | GC | | |
| 121 | CGTTAGCTTT | | | | |
| 112C (SEQ ID NO: 31) | COGCGATACA | GACCCACAQA | GTGCCATCCC | TGAGAGACCA | GACCGCTCCC |
| 1 | CCAACTCCTA | CTAAATAATA | | | |
| 161 | CAATACTCTC | | | | |
| 114C (SEQ ID NO: 32) | TGTCTCATGG | TGGGAAGGAA | CATGGTACAT | TTC | |
| 1 | CATGGATGAA | | | | |

*Repeated 3 times

*Repeated 2 times

Sequence analysis of the OC⁺ stromal cell⁻ cloned DNA sequences revealed, in addition to the novel sequences, a number of previously-described genes. The known genes identified (including type 5 acid phosphatase, gelatinase B, cystatin C (13 clones), Alu repeat sequences (11 clones), creatine kinase (6 clones) and others) are summarized in Table II. In situ hybridization (described below) directly demonstrated that gelatinase B mRNA is expressed in multinucleated osteoclasts and not in stromal cells. Although gelatinase B is a well-characterized protease, its expression at high levels in osteoclasts has not been previously described. The expression in osteoclasts of cystatin C, a cysteine protease inhibitor, is also unexpected. This finding has not yet been confirmed by in situ hybridization. Taken together, these results demonstrate that most of these identified genes are osteoclast-expressed, thereby confirming the effectiveness of the differential screening strategy for identifying DNA encoding osteoclast-specific or -related gene products. Therefore, novel genes identified by this method have a high probability of being OC-specific or related.

In addition, a minority of the genes identified by this screen are probably not expressed by OCs (Table II). For example, type III collagen (6 clones), collagen type I (1 clone), dermatansulfate (1 clone), and type VI collagen (1

clone) are more likely to originate from the stromal cells or from osteoblastic cells which are present in the tumor. These cDNA sequences survive the differential screening process either because the cells which produce them in the tumor in vivo die out during the stromal cell propagation phase, or because they stop producing their product in vitro. These clones do not constitute more than 5-10% of the all sequences selected by differential hybridization.

TABLE II

| SEQUENCE ANALYSIS OF CLONES ENCODING KNOWN SEQUENCES FROM AN OSTEOCLASTOMA cDNA LIBRARY | |
|---|----------|
| Clones with Sequence Homology to Collagenase Type IV | 25 total |
| Clones with Sequence Homology to Type 5 Tartrate Resistant Acid Phosphatase | 14 total |
| Clones with Sequence Homology to Cystatin C | 13 total |
| Clones with Sequence Homology to Alu-repeat Sequences | 11 total |
| Clones with Sequence Homology to Creatine Kinase | 6 total |
| Clones with Sequence Homology to | 6 total |

TABLE II-continued

| SEQUENCE ANALYSIS OF CLONES ENCODING KNOWN SEQUENCES FROM AN OSTEOCLASTOMA cDNA LIBRARY | |
|---|----------|
| Type III Collagen | |
| Clones with Sequence Homology to MHC Class I γ Invariant Chain | 5 total |
| Clones with Sequence Homology to MHC Class II β Chain | 3 total |
| One or Two Clone(s) with Sequence Homology to Each of the Following: | 10 total |
| $\alpha 1$ collagen type I | |
| γ interferon inducible protein | |
| osteopontin | |
| Human chondroitin/dermatansulfate | |
| α globin | |
| β glucosidase/sphingolipid activator | |
| Human CAP1 protein (Ca binding) | |
| Human EST 01024 | |
| Type VI collagen | |
| Human EST 00553 | |

Example 5—In situ Hybridization of OC-Expressed Genes

In situ hybridization was performed using probes derived from novel cloned sequences in order to determine whether the novel putative OC-specific or -related genes are differentially expressed in osteoclasts (and not expressed in the stromal cells) of human giant cell tumors. Initially, in situ hybridization was performed using antisense (positive) and sense (negative control) cRNA probes against human type IV collagenase/gelatinase B labelled with 35 S-UTP.

A thin section of human giant cell tumor reacted with the antisense probe resulted in intense labelling of all OCs, as indicated by the deposition of silver grains over these cells, but failed to label the stromal cell elements. In contrast, only minimal background labelling was observed with the sense (negative control) probe. This result confirmed that gelatinase B is expressed in human OCs.

In situ hybridization was then carried out using cRNA probes derived from 11/32 novel genes, labelled with digoxigenin UTP according to known methods.

The results of this analysis are summarized in Table III. Clones 28B, 118B, 140B, 198B, and 212B all gave positive reactions with OCs in frozen sections of a giant cell tumor, as did the positive control gelatinase B. These novel clones therefore are expressed in OCs and fulfill all criteria for OC-relatedness. 198B is repeated three times, indicating relatively high expression. Clones 4B, 37B, 88C and 98B produced positive reactions with the tumor tissue; however the signal was not well-localized to OCs. These clones are therefore not likely to be useful and are eliminated from further consideration. Clones 86B and 87B failed to give a positive reaction with any cell type, possibly indicating very low level expression. This group of clones could still be useful but may be difficult to study further. The results of this analysis show that 5/11 novel genes are expressed in OCs, indicating that ~50% of novel sequences likely to be OC-related.

To generate probes for the in situ hybridizations, cDNA derived from novel cloned osteoclast-specific or -related cDNA was subcloned into a BlueScript II SK(-) vector. The orientation of cloned inserts was determined by restriction analysis of subclones. The T7 and T3 promoters in the BlueScriptII vector was used to generate 35 S-labelled (35 S-UTP 850 Ci/mmol, Amersham, Arlington Heights, Ill.), or

UTP digoxigenin labelled cRNA probes.

TABLE III

| In Situ HYBRIDIZATION USING PROBES DERIVED FROM NOVEL SEQUENCES | | |
|---|------------------|---------------|
| Clone | Reactivity with: | |
| | Osteoclasts | Stromal Cells |
| 4B | + | + |
| 28B* | + | - |
| 37B | + | + |
| 86B | - | - |
| 87B | - | - |
| 88C | + | + |
| 98B | + | + |
| 118B* | + | - |
| 140B* | + | - |
| 198B* | + | - |
| 212B* | + | - |
| Gelatinase B* | + | - |

*OC-expressed, as indicated by reactivity with antisense probe and lack of reactivity with sense probe on OCs only.

In situ hybridization was carried out on 7 micron cryostat sections of a human osteoclastoma as described previously (Chang, L.-C. et al. *Cancer Res.* 49:6700 (1989)). Briefly, tissue was fixed in 4% paraformaldehyde and embedded in OCT (Miles Inc., Kankakee, Ill.). The sections were rehydrated, postfixed in 4% paraformaldehyde, washed, and pretreated with 10 mM DTT, 10 mM iodoacetamide, 10 mM N-ethylmaleimide and 0.1 triethanolamine-HCL. Prehybridization was done with 50% deionized formamide, 10 mM Tris-HCl, pH 7.0, 1x Denhardt's, 500 mg/ml tRNA, 80 mg/ml salmon sperm DNA, 0.3M NaCl, mM EDTA, and 100 mM DTT at 45° C. for 2 hours. Fresh hybridization solution containing 10% dextran sulfate and 1.5 ng/ml 35 S-labelled or digoxigenin labelled RNA probe was applied after heat denaturation. Sections were coverslipped and then incubated in a moistened chamber at 45°-50° C. overnight. Hybridized sections were washed four times with 50% formamide, 2x SSC, containing 10 mM DTT and 0.5% Triton X-100 at 45° C. Sections were treated with RNase A and RNase T1 to digest single-stranded RNA, washed four times in 2x SSC/10 mM DTT.

In order to detect 35 S-labelling by autoradiography, slides were dehydrated, dried, and coated with Kodak NTB-2 emulsion. The duplicate slides were split, and each set was placed in a black box with desiccant, sealed, and incubated at 4° C. for 2 days. The slides were developed (4 minutes) and fixed (5 minutes) using Kodak developer D19 and Kodak fixer. Hematoxylin and eosin were used as counterstains.

In order to detect digoxigenin-labelled probes, a Nucleic Acid Detection Kit (Boehringer-Mannheim, Cal. #1175041) was used. Slides were washed in Buffer 1 consisting of 100 mM Tris/150 mM NaCl, pH7.5, for 1 minute. 100 μ l Buffer 2 was added (made by adding 2 mg/ml blocking reagent as provided by the manufacturer) in Buffer 1 to each slide. The slides were placed on a shaker and gently swirled at 20° C.

Antibody solutions were diluted 1:100 with Buffer 2 (as provided by the manufacturer). 100 μ l of diluted antibody solution was applied to the slides and the slides were then incubated in a chamber for 1 hour at room temperature. The slides were monitored to avoid drying. After incubation with antibody solution, slides were washed in Buffer 1 for 10 minutes, then washed in Buffer 3 containing 2 mM levamisole for 2 minutes.

After washing, 100 μ l color solution was added to the slides. Color solution consisted of nitroblue/tetrazolium salt

13

(NBT) (1:225 dilution) 4.5 μ l, 5-bromo-4-chloro-3-indolyl phosphate (1:285 dilution) 3.5 μ l, levamisole 0.2 mg in Buffer 3 (as provided by the manufacturer) in a total volume of 1 ml. Color solution was prepared immediately before use.

After adding the color solution, the slides were placed in a dark, humidified chamber at 20° C. for 2-5 hours and monitored for color development. The color reaction was stopped by rinsing slides in TE Buffer.

The slides were stained for 60 seconds in 0.25% methyl green, washed with tap water, then mounted with water-based Permount (Fisher).

Example 6—Immunohistochemistry

Immunohistochemical staining was performed on frozen and paraffin embedded tissues as well as on cytospin preparations (see Table IV). The following antibodies were used: polyclonal rabbit anti-human gelatinase antibodies; Ab110 for gelatinase B; monoclonal mouse anti-human CD68 antibody (clone KP1) (DAKO, Denmark); Mo1 (anti-CD11b) and Mo2 (anti-CD14) derived from ATCC cell lines HB CRL 8026 and TIB 228/HB44. The anti-human gelatinase B antibody Ab110 was raised against a synthetic peptide with the amino acid sequence EALMYPMYRFTEGPPLHK (SEQ ID NO: 34), which is specific for human gelatinase B (Corcoran, M. L. et al. *J. Biol. Chem.* 267:515 (1992)).

Detection of the immunohistochemical staining was achieved by using a goat anti-rabbit glucose oxidase kit (Vector Laboratories, Burlingame Calif.) according to the manufacturer's directions. Briefly, the sections were rehydrated and pretested with either acetone or 0.1% trypsin. Normal goat serum was used to block nonspecific binding. Incubation with the primary antibody for 2 hours or overnight (Ab110:1/500 dilution) was followed by either a glucose oxidase labeled secondary anti-rabbit serum, or, in the case of the mouse monoclonal antibodies, were reacted with purified rabbit anti-mouse Ig before incubation with the secondary antibody.

Paraffin embedded and frozen sections from osteoclastomas (GCT) were reacted with a rabbit antiserum against gelatinase B (antibody 110) (Corcoran, M. L. et al. *J. Biol. Chem.* 267:515 (1992)), followed by color development with glucose oxidase linked reagents. The osteoclasts of a giant cell tumor were uniformly strongly positive for gelatinase B, whereas the stromal cells were unreactive. Control sections reacted with rabbit preimmune serum were negative. Identical findings were obtained for all 8 long bone giant cell tumors tested (Table IV). The osteoclasts present in three out of four central giant cell granulomas (GCG) of the mandible were also positive for gelatinase B expression. These neoplasms are similar but not identical to the long bone giant cell tumors, apart from their location in the jaws (Shafer, W. G. et al., *Textbook of Oral Pathology*, W. B. Saunders Company, Philadelphia, pp. 144-149 (1983)). In contrast, the multinucleated cells from a peripheral giant cell tumor, which is a generally non-resorptive tumor of oral soft tissue,

14

were unreactive with antibody (Shafer, W. G. et al., *Textbook of Oral Pathology*, W. B. Saunders Company, Philadelphia, pp. 144-149 (1983)).

Antibody 110 was also utilized to assess the presence of gelatinase B in normal bone (n=3) and in Paget's disease, in which there is elevated bone remodeling and increased osteoclastic activity. Strong staining for gelatinase B was observed in osteoclasts both in normal bone (mandible of a 2 year old), and in Paget's disease. Staining was again absent in controls incubated with preimmune serum. Osteoblasts did not stain in any of the tissue sections, indicating that gelatinase B expression is limited to osteoclasts in bone. Finally, peripheral blood monocytes were also reactive with antibody 110 (Table IV).

TABLE IV

DISTRIBUTION OF GELATINASE B IN VARIOUS TISSUES

| Samples | Antibodies tested Ab 110 gelatinase B |
|----------------------------|---|
| GCT frozen (n = 2) | |
| giant cells | + |
| stromal cells | - |
| GCT paraffin (n = 6) | |
| giant cells | + |
| stromal cells | - |
| central GCG (n = 4) | |
| giant cells | +(%) |
| stromal cells | - |
| peripheral GCT (n = 4) | |
| giant cells | - |
| stromal cells | - |
| Paget's disease (n = 1) | |
| osteoclasts | + |
| osteoblasts | - |
| normal bone (n = 3) | |
| osteoclasts | + |
| osteoblasts | - |
| monocytes (cytospin) | + |

Distribution of gelatinase B in multinucleated giant cells, osteoclasts, osteoblasts and stromal cells in various tissues. In general, paraffin embedded tissues were used for these experiments; exceptions are indicated.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(111) NUMBER OF SEQUENCES: 34

-continued

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 170 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:1:

| | |
|--|-----|
| GCAAAATATCT AAGTTTATTG CTTGGATTTC TAGTGAGAGC TGTTGAATTT GGTGATGTCA | 60 |
| AATGTTTCTA GGGTTTTTTT AGTTTGTTTT TATTGAAAAA TTAAATTATT TATGCTATAG | 120 |
| GTGATATTCT CTTGAATAA ACCTATAATA GAAAAATAGCA GCAGACAACA | 170 |

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 63 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:2:

| | |
|---|----|
| GTGTCAACCT GCATATCCTA AAAATGTCAA AATGCTGCAT CTGGTTAATG TCGGGGTAGG | 60 |
| GGG | 63 |

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 163 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:3:

| | |
|---|-----|
| CTTCCCTCTC TTGCTTCCTT TTCCCAAGCA GAGGTGCTCA CTCCATGGCC ACCGCCACCA | 60 |
| CAGGCCACCA GGGAGTACTG CCAGACTACT GCTGATGTTT TCTTAAGGCC CAGGGAATCT | 120 |
| CAACCAAGCTG GTGGTGAATG CTGCCTGGCA CGGGACCCCC CCC | 163 |

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 173 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:4:

| | |
|---|-----|
| TTTTATTGT AATATATGT ATTACATCCC TAGAAAAAGA ATCCAGGAT TTTCCCTCCT | 60 |
| GTGTGTTTTG GTCTTCTTTC TTCATGGTCC ATGATGCCAG CTGAGGTTGT CAGTACAATG | 120 |
| AAACCAAACT GGGGGGATGG AAGCAGATTA TTCTGCCATT TTTCCAGGTC TTT | 173 |

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 197 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double

-continued

(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

GGCTGGACAT GGGTGCCCTC CACGTCCCTC ATATCCCCAG GCACACTCTG GCCTCAGGTT      60
TTGCCCTGGC CATGTCATCT ACCTGGAGTG GGCCCTCCCC TTCTTCAGCC TTGAATCAAA      120
AGCCACTTTG TTAGGCGAGG ATTTCCAGA CCACTCATCA CATTAAAAAA TATTTTAAAA      180
ACAAAAA      197

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 132 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

TTGACAAAGC TGTTTATTTT CACCAATAAA TAGTATATGG TGATTGGGGT TTCTATTTAT      60
AAGAGTAGTG GCTATTATAT GGGGTATCAT GTTGATGCTC ATAAATAGTT CATATCTACT      120
TAATTTGCCT TC      132

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 75 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

GAAGAGAGTT GTATGTACAA CCCCACAGG CAAGGCAGCT AAATGCAGAG GGTACAGAGA      60
GATCCCCGAGG GAATT      75

```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 151 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

GGATGGAAC ATGTAGAAAT CCAGAGAAAA ACAATTTTAA AAAAAAGGTGG AAAAGTTACG      60
GCAAACCTGA GATTTTCAGCA TAAATCTTT AGTTAGAAGT GAGAGAAAGA AGAGGGAGGC      120
TGOTTGCTGT TGCACGTATC AATAGGTTAT C      151

```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 141 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

-continued

(1) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

TTCTTGATCT TTAGAACACT ATGAATAAGG AAAAAAGAAA AAACTGTTCA AAATAAAATG      60
TAGGAGCCGT GCTTTTGGAA TGCTTGAGTG AGGAGCTCAA CAAGTCCTCT CCCAAGAAAG      120
CAATGATAAA ACTTGACAAA A                                     141

```

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 162 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(1) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```

ACCCATTCTT AACAAATTTT ACTGTAAAT TTTTGGTCAA AGTTCTAAGC TTAATCACAT      60
CTCAAAGAAT AGAGGCAATA TATAGCCCAT CTACTAGAC ATACAGTATT AAAGTGGACT      120
GAATATGAGG ACAAGCTCTA GTGGTCATTA AACCCCTCAG AA                          162

```

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 157 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(1) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```

ACATATATTA ACAGCATTCA TTTGGCCAAA ATCTACACGT TTGTAGAATC CTACTGTATA      60
TAAAGTGGGA ATGTATCAAG TATAGACTAT GAAAGTGCAA ATAACAAATC AAGGTTAGAT      120
TAACITTTTT TTTTACATT ATAAAATTAA CTTGTTT                                157

```

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 75 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(1) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

CCAAATTTCT CTGGAATCCA TCCTCCCTCC CATCACCATA GCCTCGAGAC GTCATTTCTG      60
TTTGACTACT CCAGC                                             75

```

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 124 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(1) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```

AACTAACCTC CTCGACCCC TGCCTCACTC ATTTACACCA ACCACCCAAC TATCTATAAA      60
CCTGAGCCAT GGCCATCCCT TATGAGCGGC GCAGTGATTA TAGGCTTTCC CTCTAAGATA      120

```

-continued

AAAT

124

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 151 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:14:

| | |
|--|-----|
| ATTATTATTC TTTTITATG TTAGCTTAGC CATGCAAAAT TTAAGTGTGA AGCAGTTAAT | 60 |
| AAAAACACACA TCCCATTTGAA GGGTTTTGTA CATTTTCAGTC CTTACAAATA ACAAAGCAAT | 120 |
| GATAAACCCG GCACGTCCTG ATAGGAAATT C | 151 |

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 105 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:15:

| | |
|--|-----|
| CGTGACACAA ACATGCATTC OTTTTATTCA TAAACAGCC TGGTTTCCTA AAACAATACA | 60 |
| AACAGCATGT TCATCAACAG GAAGCTGGCC GTGGGCAGGG GGGCC | 105 |

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 246 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:16:

| | |
|---|-----|
| ATAGGTTAGA TTCTCATTCA CCGACTAGT TAGCTTTAAG CACCCTAGAG GACTAGGGTA | 60 |
| ATCTGACTTC TCACCTCCTA AGTTCCCTCT TATATCCTCA AGGTAGAAAT GTCTATGTTT | 120 |
| TCTACTCCAA TTCATAAATC TATTCATAAG TCTTTGGTAC AAGTTACATG ATAAAAAGAA | 180 |
| ATGTGATTTG TCTTCCCTTC TTTGCACITT TGAAATAAAG TATTTATCTC CTCTCTACAG | 240 |
| TTTAAT | 246 |

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 188 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:17:

| | |
|---|-----|
| GTCCAGTATA AAGGAAAGCG TTAAGTCOGT AAGCTAGAGG ATTGTAAATA TCTTTTATGT | 60 |
| CCTCTAGATA AAACACCCGA TTAACAGATG TTAACCTTTT ATGTTTGTAT TTGCTTTAAA | 120 |
| AATGGCCTTC TACACATTAG CTCCAGCTAA AAAGACACAT TGAGAGCTTA GAGGATAGTC | 180 |

-continued

TCTGGAGC

188

(2) INFORMATION FOR SEQ ID NO:18:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 212 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(1.1) MOLECULE TYPE: DNA (genomic)

(1.1.1) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```

GCACCTTGGAA GGGAGTTGOT GTGCTATTTT TGAAGCAGAT GTGCTGATAC TGAGATTGTC      60
TGTTCACTTT CCCCATTGT TTGTGCTTCA AATGATCCTT CCTACTTTGC TTCTCTCCAC      120
CCATGACCTT TTTCACTGTG GCCATCAAGG ACTTTCCTGA CAGCTTGTGT ACTCTTAGGC      180
TAAGAGATGT GACTACAGCC TGCCCTGAC TG                                212

```

(2) INFORMATION FOR SEQ ID NO:19:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 203 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(1.1) MOLECULE TYPE: DNA (genomic)

(1.1.1) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```

TGTTAGTTTT TAGGAAGGCC TGTCTTCTGG GAGTGAGGTT TATTAGTCCA CTTCTTGGAG      60
CTAGACGTCC TATAGTTAGT CACTGGGGAT GGTGAAAGAG GGAGAAGAGG AAGGGCGAAG      120
GGAAGGGCTC TTTGCTAGTA TCTCCATTTT TAGAAGATGG TTTAGATGAT AACCACAGGT      180
CTATATGAGC ATAGTAAGGC TGT                                203

```

(2) INFORMATION FOR SEQ ID NO:20:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 177 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(1.1) MOLECULE TYPE: DNA (genomic)

(1.1.1) SEQUENCE DESCRIPTION: SEQ ID NO:20:

```

CCTATTTCTG ATCCTGACTT TGGACAAGGC CCTTCAGCCA GAAGACTGAC AAAGTCATCC      60
TCCCTCTACC AGAGCGTGCA CTGTGTATCC TAAAATAAGC TTCATCTCCG GCTGTGCCTT      120
GGGTGGAAGG GGCAGGATTC TGCAGCTGCT TTTGCATTTT TCTTCCTAAA TTTCATT      177

```

(2) INFORMATION FOR SEQ ID NO:21:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 106 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(1.1) MOLECULE TYPE: DNA (genomic)

(1.1.1) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```

CGGAGCGTAG GTGTGTTTAT TCCTGTACAA ATCATTACAA AACCAAGTCT GGGGCAGTCA      60
CCGCCCCCAC CCATCACCCC AOTGCAATGG CTAGCTGCTG GCCTTT                                106

```

-continued

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 139 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```
TTAGTTCACT CAAACACAGC AACCCCTTT GGCAGTCTG CCACTGGGGT CATGCCGTT      60
GTGGCAGCTG GGGAGGTTTC CCCAACACCC TCCTCTGCTT CCCTGTGTGT CGGGGTCTCA    120
GGAGCTGACC CAGAGTGGG                                     139
```

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 177 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```
GCTGAATGTT TAAGAGAGAT TTGGTCTTA AAGGCTTCAT CATGAAAGTG TACATGCATA      60
TGCAAAGTGTG AATTACGTGG TATGGATGGT TGCTTGTTTA TTAATAAAG ATGTACAGCA    120
AAGTGCCCGT TTAGAGTCCT CTTAATATTG ATGTCCTAAC ACTGGGTCTG CTTATGC      177
```

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 167 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```
GGCACTGGGA TATGGAATCC AGAAGGGAAA CAACTACTGG ATAATTAAAA ACACTGGGG      60
AGAAAACTGG GGAACAAAAG GATATATCCT CATGGCTCGA AATAAGAACA ACGCCTGTGG    120
CATTGCCAAC CTGCCAGCT TCCCAAGAT GTGACTCCAG CCAGAAA                        167
```

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 151 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```
GCCAGGGCGG ACCGTCTTTA TTCCTCTCCT GCCTCAGAGG TCAGGAAGGA GGTCTGGCAG      60
GACCTGCAGT GGGCCCTAGT CATCTGTGGC AGCGAAGGTG AAGGGACTCA CCTTGTCCGC    120
COTGCCTGAG TAGAATTOT TCTGGAATTC C                                     151
```

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

-continued

(A) LENGTH: 156 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:26:

| | |
|---|-----|
| A A C T C T T T C A C A C T C T G G T A T T T T T A G T T T A A C A A T A T A T G T G T T G T G T C T T G G A A A T T A | 60 |
| G T T C A T A T C A A T T C A T A T T G A G C T G T C T C A T T C T T T T T T A A T G G T C A T A T A C A G T A G T A | 120 |
| T T C A A T T A T A A G A A T A T A T C C T A A T A C T T T T T A A A A A | 156 |

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 150 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:27:

| | |
|---|-----|
| G G A T A A G A A A G A A G G C C T G A G G C T A G G G G C C G G G G C T G G C C T G C G T C T C A G T C C T G G G A | 60 |
| C G C A G C A G C C C G C A C A G G T T G A G A G G G G C A C T T C C T C T T G C T T A G G T T G G T G A G G A T C T G | 120 |
| G T C C T G G T T G G C C G G T G G A G A G C C A C A A A A | 150 |

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 212 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:28:

| | |
|---|-----|
| G C A C T T G G A A G G G A G T T G G T G T G C T A T T T T T G A A G C A G A T G T G G T G A T A C T G A G A T T G T C | 60 |
| T G T T C A G T T T C C C C A T T T G T T T G T C T T C A A A T G A T C C E T T C C T A C T T T G C T T C T C C A C | 120 |
| C C A T G A C C T T T T C A C T G T G G C C A T C A A G G A C T T T C C T G A C A G C T T G T G T A C T C T T A G G C | 180 |
| T A A G A G A T G T G A C T A C A G C C T G C C C C T O A C T G | 212 |

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 157 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:29:

| | |
|---|-----|
| A T C C C T G G C T G T G G A T A G T G C T T T T G T G T A G C A A A T G C T C C T C C T T A A G G T T A T A G G G C | 60 |
| T C C C T G A G T T T G G G A G T G T G G A A G T A C T A C T T A A C T G T C T G T C C T G C T T G C T G T C G T T A | 120 |
| T C G T T T T C T G G T A T G T T G T G C T A A C A A T A A G A A T A C | 157 |

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 152 base pairs
 (B) TYPE: nucleic acid

-continued

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:30:

| | |
|---|-----|
| GGCTGGGCAT CCCTCTCCTC CTCCATCCCC ATACATCACC AGGTCTAATG TTTACAAACG | 60 |
| GTCCAGCCCC GGCTCTGAAG CCAAAGGCCC TCCGTGCCAC GGTGGCTOTO AGTATTCCTC | 120 |
| CCTTAGCTTT CCCATAAGGT TGGAGTATCT GC | 152 |

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 90 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:31:

| | |
|---|----|
| CCAACTCCTA CCGCGATACA GACCCACAGA GTGCCATCCC TGAGAGACCA GACCGCTCCC | 60 |
| CAATACTCTC CTAAAATAAA CATGAAGCAC | 90 |

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:32:

| | |
|---|----|
| CATGGATGAA TGTCTCATGG TGGGAAGGAA CATGGTACAT TTC | 43 |
|---|----|

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2333 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:33:

| | |
|--|-----|
| AGACACCTCT GCCCTCACCA TGAGCCTCTG GCAGCCCCTG GTCCTGGTGC TCCTGGTGCT | 60 |
| GGGCTGCTGC TTTGCTGCCC CCAGACAGCG CCAGTCCACC CTTGTGCTCT TCCCTGGAGA | 120 |
| CCTGAGAACC AATCTCACCG ACAGGCAGCT GGCAGAGGAA TACCTGTACC GCTATGGTTA | 180 |
| CACTCGGGTG GCAGAGATGC GTGGAGAGTC GAAATCTCTG GGGCCTGCGC TGCTGCTTCT | 240 |
| CCAGAAGCAA CTGTCCCTGC CCGAGACCGG TGAAGTGAAT ACGGCCACGC TGAAGGCCAT | 300 |
| GCGAAGCCCA CGGTGCGGGG TCCCAGACCT GGGCAGATTG CAAACCTTTG AGGGCGACCT | 360 |
| CAAAGTGGCAC CACCACAACA TCACCTATTG GATCCAAAAC TACTCGGAAG ACTTGCCGCG | 420 |
| GCGGGTGATT GACGACGCCT TTGCCCAGCG CTTGCGACTG TGGAGCGCGG TGACGCCGCT | 480 |
| CACCTTCACT CCGGTGTACA GCGGGGACGC AGACATCGTC ATCCAGTTTG GTGTCGCGGA | 540 |
| GCACGGAGAC GGGTATCCCT TCGACGGGAA GGACGGGCTC CTGGCACACG CCTTTCCTCC | 600 |
| TGGCCCCGGC ATTCAGGGAG ACGCCCATTT CGACGATGAC GAGTTGTGGT CCCTGGGCAA | 660 |

-continued

| | | | | | | |
|------------|-------------|------------|-------------|------------|-------------|------|
| GGGCOTCGTG | GTTCCAACCTC | GTTTGGAAA | CGCAGATGGC | GCGGCCTGCC | ACTTCCCCTT | 720 |
| CATCTTCGAG | GGCCGCTCCT | ACTCTGCCTG | CACCACCGAC | GGTCGCTCCG | ACGGGTTGCC | 780 |
| CTGGTGCAQT | ACCACGGCCA | ACTACGACAC | CGACGACCGG | TTTGGCTTCT | GCCCCAAGCA | 840 |
| GAGACTCTAC | ACCCGGGACG | GCAATGCTGA | TGGGAAACCC | TGCCAGTTTC | CATTTCATCTT | 900 |
| CCAAGGCCAA | TCCTACTCCG | CCTGCACCAC | GGACGGTCGC | TCCGACGGCT | ACCGCTGGTG | 960 |
| CGCCACCACC | GCCAACCTACG | ACCGGGACAA | GCTCTTTCGGC | TTCTGCCCCG | CCCGAGCTGA | 1020 |
| CTCGACGCTG | ATGGGCGGCA | ACTCGGCGGG | GGAGCTGTGC | GTCTTCCCCT | TCACITTCCT | 1080 |
| GGGTAAGGAG | TACTCGACCT | GTACCAGCGA | GGGCCGCGGA | GATGGGCGCC | TCTGCTGCGC | 1140 |
| TACCACCTCG | AACTTTGACA | GCGACAAGAA | GTGGGGCTTC | TGCCCCGACC | AAGGATACAG | 1200 |
| TTTGTTCCTC | GTGGCGGCGC | ATGAGTTCGG | CCACGCGCTG | GGCTTAGATC | ATTCTCTAGT | 1260 |
| CCCGGAGGCG | CTCATGTACC | CTATGTACCG | CTTCACTGAG | GGCCCCCCTT | TGCATAAAGG | 1320 |
| CGACGTGAAT | GGCATCCGCG | ACCTCTATGG | TCCTCGCCCT | GAACCTGAAC | CACGGCCTCC | 1380 |
| AACCACCACC | ACACCGCAGC | CCACGGCTCC | CCCGACGGTC | TGCCCCACCG | GACCCCCCAC | 1440 |
| TGTCCACCCC | TCAGAGCGCC | CCACAGCTGG | CCCCACAGGT | CCCCCCTCAG | CTGCCCCCAC | 1500 |
| AGGTCCCCCC | ACTGCTGGCC | CTTCTACGGC | CACTACTGTG | CCTTTGAGTC | CGGTGGACGA | 1560 |
| TGCCTGCAAC | GTGAACATCT | TCGACGCCAT | CGCGGAGATT | GGGAACCAGC | TGTATTTGTT | 1620 |
| CAAGGATGGG | AAGTACTGGC | GATTCTCTGA | GGGCAGGGGG | AGCCGGCCGC | AGGGCCCCCT | 1680 |
| CCTTATCGCC | GACAAGTGCC | CCGCGCTGCC | CCGCAAGCTG | GACTCGGTCT | TTGAGGAGCC | 1740 |
| GCTCTCCAAG | AAGCTTTTCT | TCTTCTCTGG | GCGCCAGGTG | TGGGTGTACA | CAGGCGCGTC | 1800 |
| GGTGCTGGGC | CCGAGGCGTC | TGGACAAGCT | GGGCCTGGGA | GCCGACGTGG | CCCAGGTGAC | 1860 |
| CGGGGCCCCC | CGGAGTGCCA | GGGGGAAGAT | GCTGCTGTTC | AGCGGGCGGC | GCCTCTGGAG | 1920 |
| GTTCGACGTG | AAGGCGCAGG | TGGTGGATCC | CCGGAGCGCC | AOCGAAGTGG | ACCGGATGTT | 1980 |
| CCCCGGGGTG | CCTTTGGACA | CGCACGACGT | CTTCCAGTAC | CGAGAGAAAG | CCTATTTCTG | 2040 |
| CCAGGACCGC | TTCTACTGGC | GCGTGAAGTC | CCGGAGTGAG | TTGAACCAGG | TGGACCAAGT | 2100 |
| GGGCTACGTG | ACCTATGACA | TCCTGCAGTG | CCCTGAGGAC | TAGGGCTCCC | GTCTGTCTTT | 2160 |
| GCAGTGCCAT | GTAAATCCCC | ACTGGGACCA | ACCCTGGGGA | AAGAGCCAGT | TTGCCGGATA | 2220 |
| CAAAC TGGA | TTCTGTTCTG | GAGGAAAGGG | AGGAGTGGAG | GTGGGCTGGG | CCCTCTCTTC | 2280 |
| TCACCTTTGT | TTTTTGTGG | AGTGTCTCTA | ATAAACTTGG | ATTCTCTAAC | CTTT | 2334 |

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(iii) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Glu Ala Leu Met Tyr Pro Met Tyr Arg Phe Thr Glu Gly Pro Pro Leu
 1 5 10 15
 His Lys

We claim:
 1. An isolated osteoclast-specific or -related DNA sequence, or its complementary sequence, the DNA 65 sequence comprising a nucleic acid sequence selected from the group consisting of:

a) DNA sequences set forth in the group consisting of SEQ ID NOS. 12, 14, 16 and 17, or their complementary strands; and

33

b) DNA sequences which hybridize under standard conditions to the DNA sequences defined in a).

2. A DNA construct capable of replicating, in a host cell, osteoclast-specific or -related DNA, said construct comprising:

a) a DNA sequence of claim 1; and

b) sequences, in addition to said DNA sequence, necessary for transforming or transfecting a host cell, and for replicating, in a host cell, said DNA sequence.

3. A DNA construct capable of replicating and expressing, in a host cell, osteoclast-specific or -related DNA, said construct comprising:

34

a) a DNA sequence of claim 2; and

b) sequences, in addition to said DNA sequence, necessary for transforming or transfecting a host cell, and for replicating and expressing, in a host cell, said DNA sequence.

4. A cell stably transformed or transfected with a DNA construct according to claim 3.

5. A cell stably transformed or transfected with a DNA construct according to claim 4.

* * * * *